Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Sickle cell patients share delight over approval of new treatment - Health officials have approved a £1.65 million treatment ...

One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

It was mere coincidence that 95-year-old Gene Schroeder died during the week of the NFL Pro Bowl games. He was not only a ...

It is believed around 1,700 people could be eligible for the treatment, while the NHS estimates around 50 people a year will ...

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

Everything you need to know about agonising sickle cell disease and the ‘revolutionary’ new DNA therapy that's being rolled ...